Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti‐CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double‐Blind , Placebo‐Controlled , Phase II Trial
Arthritis & Rheumatology · 2023
DOI: 10.1002/art.42557 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2023. Verfasst von David R Jayne und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Lupus Nephritis. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim, NIHR Cambridge Biomedical Research Centre.
Abstract (Originalsprache)
Objective
To characterize its dose‐response relationship, BI 655064 (an anti‐CD40 monoclonal antibody) was tested as an add‐on to mycophenolate and glucocorticoids in patients with active lupus nephritis (LN).
Methods
A total of 121 patients were randomized (2:1:1:2) to receive placebo or BI 655064 120, 180, or 240 mg and received a weekly loading dose for 3 weeks followed by dosing every 2 weeks for the 120 and 180 mg groups, and 120 mg weekly for the 240 mg group. The primary endpoint was complete renal response (CRR) at week 52. Secondary endpoints included CRR at week 26.
Results
A dose‐response relationship with CRR at week 52 was not shown (BI 655064 120 mg, 38.3%; 180 mg, 45.0%; 240 mg, 44.6%; placebo, 48.3%). At week 26, 28.6% (120 mg), 50.0% (180 mg), 35.0% (240 mg), and 37.5% (placebo) achieved CRR. The unexpected high placebo response prompted a post hoc analysis evaluating confirmed CRR (cCRR, at weeks 46 and 52). cCRR was achieved in 22.5% (120 mg), 44.3% (180 mg), 38.2% (240 mg), and 29.1% (placebo) of patients. Most patients reported ≥1 adverse event (BI 655064, 85.7–95.0%; placebo, 97.5%), most frequently infections and infestations (BI 655064 61.9–75.0%; placebo 60%). Compared with other groups, higher rates of serious (20% vs. 7.5–10%) and severe infections (10% vs. 4.8–5.0%) were reported with 240 mg BI 655064.
Conclusion
The trial failed to demonstrate a dose‐response relationship for the primary CRR endpoint. Post hoc analyses suggest a potential benefit of BI 655064 180 mg in patients with active LN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Cambridge, Cambridge, UK.
- Boehringer Ingelheim International GmbH, Biberach, Germany.
- Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubiran", Mexico City, Mexico.
- Department of Pathology and Medical Biology, University of Groningen, University Medical Center, Groningen, the Netherlands.
- Department of Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
ORCID-Profile: David R Jayne, Richard Furie
Förderung
- Boehringer Ingelheim
- NIHR Cambridge Biomedical Research Centre
Zitieren
APA
Jayne, D. R., Steffgen, J., Romero-Diaz, J., Bajema, I., Boumpas, D. T., Noppakun, K., Amano, H., Gomez, H. M., Satirapoj, B., Avihingsanon, Y., Chawanasuntorapoj, R., Madero, M., Naumnik, B., Recto, R., Fagan, N., Revollo, I., Wu, J., Visvanathan, S., & Furie, R. (2023). Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti‐CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double‐Blind , Placebo‐Controlled , Phase II Trial. Arthritis & Rheumatology. https://doi.org/10.1002/art.42557
Vancouver
Jayne DR, Steffgen J, Romero-Diaz J, Bajema I, Boumpas DT, Noppakun K, et al. Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti‐CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double‐Blind , Placebo‐Controlled , Phase II Trial. Arthritis & Rheumatology. 2023. doi:10.1002/art.42557
BibTeX
@article{Jayne2023,
author = {Jayne, David R and Steffgen, Jürgen and Romero-Diaz, Juanita and Bajema, Ingeborg and Boumpas, Dimitrios T and Noppakun, Kajohnsak and Amano, Hirofumi and Gomez, Harold Michael and Satirapoj, Bancha and Avihingsanon, Yingyos and Chawanasuntorapoj, Ratana and Madero, Magdalena and Naumnik, Beata and Recto, Rhona and Fagan, Nora and Revollo, Ivette and Wu, Jing and Visvanathan, Sudha and Furie, Richard},
title = {Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti‐CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double‐Blind , Placebo‐Controlled , Phase II Trial},
journal = {Arthritis & Rheumatology},
year = {2023},
doi = {10.1002/art.42557}
}
EUVIMED